Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Septic shock, defined by the Sepsis-3 criteria~  * proven or suspected infection, with modification of the SOFA score ≥ 2 points,~ * with persistent hypotension requiring vasopressors to maintain MAP ≥ 65 mmHg~ * and a serum lactate level \> 2 mmol/L despite adequate vascular filling~* Adequate vascular filling: ≥ 30ml/kg, OR absence of preload-dependency criteria at time of assessment (respiratory variability of the inferior vena cava, passive leg lift, pulsed pressure variation)~* Catecholamine resistance, defined by the need for a dose of norepinephrine ≥ 0,5 µg/kg/min for more than 2 consecutive hours within 24 hours of admission to intensive care unit~* persistence of circulatory failure with at least one of the following criteria present in the 2 hours prior to randomisation: hyperlactatemia \> 2mmol/l, and/or mottling (≥ 1 score), and/or oliguria (diuresis \< 0,5 ml/kg/h over the last 2 hours)~* Invasive Mechanical ventilation~* Under sedation by midazolam or propofol~* Informed consent obtained from a relative for patient included in an emergency~* Patient affiliated to the national health insurance system~Exclusion Criteria:~* Cardiac arrest before inclusion and occurring before septic shock criteria are met~* Cardiac index \< 2.2 l/min/m² after volume correction, or left ventricular ejection fraction \< 40% on echocardiography~* Bradycardia \< 55 bpm (apart from treatment with β-blocker) or 2nd or 3rd degree BAV not equipped~* Proven or suspected decompensation of coronary heart disease~* Acute cerebrovascular condition within 2 weeks prior to inclusion~* Severe hepatic insufficiency with TP and factor V \<50% in the absence of DIC (disseminated intravascular coagulation)~* Patient on adrenaline or vasopressors at the time of inclusion (epinephrine or vasopressin stopped prior to inclusion is not a criterion for non-inclusion)~* Patient on non-selective MAOI iproniazid within 15 days of inclusion~* Patient for whom a decision has been made to limit the use of therapies~* Hypersensitivity to dexmedetomidine or phenylephrine~* Patient on dexmedetomidine before inclusion~* Person subject to a legal protection measure (curatorship, guardianship)~* Person subject to limited judicial protection~* Pregnant, parturient or breastfeeding woman~* Patient with suspected or confirmed mesenteric ischemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).